122 related articles for article (PubMed ID: 7623780)
1. Studies on neuropeptide Y receptors in a mouse adrenocortical cell line.
Weng G; Yee F; Michl P; Reis D; Wahlestedt C
Mol Pharmacol; 1995 Jul; 48(1):9-14. PubMed ID: 7623780
[TBL] [Abstract][Full Text] [Related]
2. Role of the C terminus in neuropeptide Y Y1 receptor desensitization and internalization.
Holliday ND; Lam CW; Tough IR; Cox HM
Mol Pharmacol; 2005 Mar; 67(3):655-64. PubMed ID: 15576634
[TBL] [Abstract][Full Text] [Related]
3. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y and the retinal pigment epithelium: receptor subtypes, signaling, and bioelectrical responses.
Ammar DA; Hughes BA; Thompson DA
Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1870-8. PubMed ID: 9727410
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors.
Kempná P; Körner M; Waser B; Hofer G; Nuoffer JM; Reubi JC; Flück CE
Mol Cell Endocrinol; 2010 Jan; 314(1):101-9. PubMed ID: 19699258
[TBL] [Abstract][Full Text] [Related]
6. Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line.
Amlal H; Faroqui S; Balasubramaniam A; Sheriff S
Cancer Res; 2006 Apr; 66(7):3706-14. PubMed ID: 16585197
[TBL] [Abstract][Full Text] [Related]
7. c-Myc protein is stabilized by fibroblast growth factor 2 and destabilized by ACTH to control cell cycle in mouse Y1 adrenocortical cells.
Lepique AP; Moraes MS; Rocha KM; Eichler CB; Hajj GN; Schwindt TT; Armelin HA
J Mol Endocrinol; 2004 Dec; 33(3):623-38. PubMed ID: 15591023
[TBL] [Abstract][Full Text] [Related]
8. Characterization of G protein and phospholipase C-coupled agonist binding to the Y1 neuropeptide Y receptor in rat brain: sensitivity to G protein activators and inhibitors and to inhibitors of phospholipase C.
Parker SL; Parker MS; Sweatman T; Crowley WR
J Pharmacol Exp Ther; 1998 Jul; 286(1):382-91. PubMed ID: 9655883
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors.
Dimitrijević M; Stanojević S; Vujić V; Beck-Sickinger A; von Hörsten S
Regul Pept; 2005 Jan; 124(1-3):163-72. PubMed ID: 15544855
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y receptor gene regulation in mouse adrenocortical Y-1 cells.
Weng G; Feinstein D; Reis D; Wahlestedt C
Regul Pept; 1996 May; 63(1):53-6. PubMed ID: 8795089
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y receptor-mediated sensitization of ATP-stimulated inositol phosphate formation.
Drakulich DA; Walls AM; Toews ML; Hexum TD
J Pharmacol Exp Ther; 2003 Nov; 307(2):559-65. PubMed ID: 12970392
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review).
Spinazzi R; Andreis PG; Nussdorfer GG
Int J Mol Med; 2005 Jan; 15(1):3-13. PubMed ID: 15583821
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
[TBL] [Abstract][Full Text] [Related]
18. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture.
Abounader R; Elhusseiny A; Cohen Z; Olivier A; Stanimirovic D; Quirion R; Hamel E
J Cereb Blood Flow Metab; 1999 Feb; 19(2):155-63. PubMed ID: 10027771
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
Malmström RE
Acta Physiol Scand Suppl; 1997; 636():1-55. PubMed ID: 9179320
[TBL] [Abstract][Full Text] [Related]
20. Vascular neuropeptide Y Y1-receptors in the rat kidney: vasoconstrictor effects and expression of Y1-receptor mRNA.
Modin A; Malmström RE; Meister B
Neuropeptides; 1999 Aug; 33(4):253-9. PubMed ID: 10657500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
